• Loading stock data...
Est. 2004

LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

Tuesday 09/25/2018
SMALL CAP MARKET NEWS

We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.


LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

CTXR

  • 2:04 PM

    Worldwide License for Mino-Lok™ is Now Complete CRANFORD, N.J., March 23, 2017, CTXR, /PRNewswire/ — Citius Pharmaceuticals, Inc. (“Citius”) (OTC BB: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that it has recently concluded negotiations to add South America to its worldwide license for Mino-Lok™.  South America was the only territory that was not included in the original sub-license between Novel Anti-Infective Technologies, LLC, an affiliate of MD Anderson Cancer Center (“MDACC”), and

    Read more
  • 3:09 PM

    Manufacturing Finalized and Site Recruitment Initiated PR Newswire, CTXR CRANFORD, N.J., Dec. 8, 2016 CRANFORD, N.J., Dec. 8, 2016 /PRNewswire/ — Citius Pharmaceuticals, Inc. (“Citius”) (OTC BB: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, provided details of its phase 3 trial for Mino-Lok™, an antibiotic lock solution used to salvage infected central venous catheters (CVCs) and to treat catheter related bloodstream infections (CRBSIs).  Mino-Lok is being developed as an adjunctive therapy for the treatment of

    Read more
  • 1:42 PM

    Site Recruitment is Underway CRANFORD, N.J., Sept. 13, 2016, CTXR, /PRNewswire/ — Citius Pharmaceuticals, Inc. (“Citius”) (OTC BB: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that it has initiated the pivotal Phase 3 clinical trial Mino-Lok™, an antibiotic lock solution used to salvage infected central venous catheters (CVCs) and to treat catheter related bloodstream infections (CRBSIs). Mino-Lok is being developed as an adjunctive therapy for the treatment of catheter-related or

    Read more
  • 7:26 PM

    Two Contract Manufacturing Organizations Engaged to Produce Clinical Trial Material PR Newswire CRANFORD, N.J., Sept. 8, 2016 CRANFORD, N.J., Sept. 8, 2016, CTXR, /PRNewswire/ — Citius Pharmaceuticals, Inc. (“Citius”) (OTC QB: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that it has initiated manufacturing for the company’s clinical trial of Mino-Lok ™, an antibiotic lock solution used to salvage central venous catheters (CVCs) and to treat catheter related bloodstream infections (CRBSIs).

    Read more
  • 3:13 PM

    CRANFORD, N.J., Sept. 7, 2016, CTXR, /PRNewswire/ — Citius Pharmaceuticals, Inc. (“Citius”) (OTC QB: CTXR), a specialty pharmaceutical company dedicated to developing and commercializing adjunctive cancer care and critical care drug products, announced today that its Chairman, Len Mazur, will present at the Rodman & Renshaw 18th Annual Global Investment Conference. The Conference will be held on September 11-13, 2016 at the Lotte New York Palace Hotel, New York City. Event: Rodman & Renshaw 18th Annual Global Investment Conference Location:

    Read more
  • 7:28 PM

    CHICAGO, IL, Jan 30, 2015 (Marketwired via COMTEX) — Veltex Corporation — (OTC PINK: VLXC) — Veltex Corporation (“the Company”) announced today that the corporation has materially revised upward the accrued interest on the federal judgments reached in California. The accrued interest will now be reflected as $25,942,898 up from $2,281,950 or an increase of $23,660,948. The changes will be reflected in the September 30, 2014 accounting. The Company’s legal settlement receivables relate to various lawsuits. For the purpose of this

    Read more
Public Wire Banner